Compound Evidence File
#EC-2026-0122
Clomid
Filed under Oral Tablets. The bureau holds 117 laboratory returns for this compound from 42 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
42 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Mar 2026 | 26 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Mar 2026 | 14 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Apr 2026 | 21 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 13 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Dec 2025 | 1 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 10.0 | 10.0 | 3 Apr 2026 | 14 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Mar 2026 | 10 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 3 Dec 2025 | 2 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 13 Mar 2026 | 9 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Feb 2026 | 25 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Jul 2026 | 14 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Nov 2025 | 23 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Dec 2025 | 27 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Jan 2026 | 11 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Dec 2025 | 22 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Feb 2026 | 19 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Mar 2026 | 23 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Apr 2026 | 5 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Jan 2026 | 10 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 9 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Jun 2026 | 26 Jul 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.7 | 9.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 8.9 | 8.9 | 8.9 | 21 May 2025 | 21 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.8 | 7.4 | 10.0 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.7 | 8.0 | 9.3 | 23 May 2026 | 23 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 3 | 8.4 | 6.9 | 9.8 | 27 Feb 2025 | 19 Jan 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.2 | 6.8 | 9.3 | 24 May 2026 | 24 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 8.1 | 8.1 | 8.1 | 13 Jun 2025 | 13 Jun 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 8.0 | 8.0 | 8.0 | 21 May 2025 | 21 May 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.0 | 8.0 | 8.0 | 25 Apr 2025 | 25 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 7.9 | 6.7 | 8.6 | 25 May 2026 | 25 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 3 | 7.3 | 5.4 | 8.5 | 16 Mar 2025 | 23 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 1 | 7.2 | 7.2 | 7.2 | 2 Jul 2025 | 2 Jul 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 6.5 | 6.5 | 6.5 | 6 May 2025 | 6 May 2025 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 5.6 | 5.6 | 5.6 | 2 Apr 2025 | 2 Apr 2025 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 5.4 | 5.4 | 5.4 | 8 Jul 2025 | 8 Jul 2025 |
| HXNetCASE #VI-2026-0061 | X | 2 | 4.3 | 3.8 | 4.9 | 16 Mar 2025 | 21 May 2026 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 2.6 | 2.6 | 2.6 | 20 Jun 2025 | 20 Jun 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 2.5 | 2.5 | 2.5 | 20 Jun 2025 | 20 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.2 | 0.2 | 0.2 | 6 May 2025 | 6 May 2025 |
Open any subject to view the batch-level evidence for Clomid alone.